Problematic PSA . . . and other stories | The BMJ
Problematic PSA . . . and other stories | The BMJ: The problem with prostate specific antigen screening (PSA) is selecting a cut-off that provides adequate sensitivity without leading to the over diagnosis of cancers that are unlikely to cause harm. A re-analysis of data from a large trial in the US finds that men aged 55 to 60 whose PSA was less than 2 ng/ml at initial testing were very unlikely to develop clinically significant prostate cancer over 13 years of follow-up ( JAMA Netw Open doi:10.1001/jamanetworkopen.2019.19284). The investigators hope this could improve PSA testing in younger men if those with low baseline PSA levels were classified …
Comments
Post a Comment